The cydy cancer trial applicants are tested for solid tumors that express/assay CCR5 If the tumor robustly expresses CCR5 presence, the applicant will likely be eligible to participate in the trial. CCR5 expression/assay is the gateway to the cydy cancer trial. Therefore IMHO the MOA for leronlimab cancer therapy is the same as covid thereapy. All imo and as per Amarex instructions to a family member applicant.